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Abstract
Background: Non alcoholic steatohepatitis is hypothesised to develop via a mechanism involving fat accumulation
and oxidative stress. The current study aimed to investigate if an increase in oxidative stress was associated with
changes in the expression of liver fatty acid binding protein in a rat model of non alcoholic steatohepatitis and
whether cocoa supplementation attenuated those changes.
Methods: Female Sprague Dawley rats were fed a high fat control diet, a high fat methionine choline deficient
diet, or one of four 12.5% cocoa supplementation regimes in combination with the high fat methionine choline
deficient diet.
Results: Liver fatty acid binding protein mRNA and protein levels were reduced in the liver of animals with fatty
liver disease when compared to controls. Increased hepatic fat content was accompanied by higher levels of
oxidative stress in animals with fatty liver disease when compared to controls. An inverse association was found
between the levels of hepatic liver fatty acid binding protein and the level of hepatic oxidative stress in fatty liver
disease. Elevated NADPH oxidase protein levels were detected in the liver of animals with increased severity in
inflammation and fibrosis. Cocoa supplementation was associated with partial attenuation of these pathological
changes, although the severity of liver disease induced by the methionine choline deficient diet prevented
complete reversal of any disease associated changes. Red blood cell glutathione was increased by cocoa
supplementation, whereas liver glutathione was reduced by cocoa compared to methionine choline deficient diet
fed animals.
Conclusion: These findings suggest a potential role for liver fatty acid binding protein and NADPH oxidase in the
development of non alcoholic steatohepatitis. Furthermore, cocoa supplementation may have be of therapeutic
benefit in less sever forms of NASH.
Keywords: Non alcoholic steatohepatitis, NASH, oxidative stress, antioxidant, liver fatty acid binding protein,
NADPH oxidase, cocoa
Background
Non alcoholic fatty liver disease (NAFLD) involves a
spectrum of conditions ranging from simple fat accumu-
lation in the liver to end stage liver failure and cirrhosis.
NAFLD can lead into the development of non alcoholic
steatohepatitis (NASH) [1]. NASH is an emerging health
concern and it is believed that its prevalence is on the
rise due to escalating obesity rates [2]. Estimated
NAFLD prevalence in Western countries is between 17-
33% [3]. NAFLD accounts for up to 20%, and NASH
accounts for 2-3% of liver test abnormalities in most
developed countries [4].
NASH is typically reported in obese individuals suffer-
ing from one or a combination of type 2 diabetes, insu-
lin resistance and dyslipidaemia, but is not restricted to
this group [2]. There is often an increase in aspartate
aminotransferase (AST) and alanine aminotransferase
(ALT) [5]. Lipid accumulation occurs early in NASH as
part of the development of the disease [6]. The two hit
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disease model postulates that steatosis is a trigger for
the establishment of NASH and the increased levels of
fat infiltration cause damage to the liver by forming fat
droplets within the hepatic tissue, thus setting off the
second hit of the disease by causing lipotoxicity. In addi-
tion, cytokines and reactive oxygen species (ROS) create
a pro-oxidant state that can activate stellate cells to pro-
duce fibrotic scar tissue [7].
Liver fatty acid binding protein (LFABP) accounts for
3-5% of the cytosolic protein content in hepatocytes.
LFABP is transcriptionaly regulated by the nuclear hor-
mone receptor, peroxisome proliferator-activated protein
a (PPAR-a), and is responsible for intracellular traffick-
ing of long chain fatty acids [8]. Rat LFABP has recently
been described as an endogenous antioxidant [9], and
may be useful in states of extreme oxidative stress when
intracellular antioxidants such as superoxide dismutase,
glutathione and catalase cannot quench excessive quan-
tities of ROS. This antioxidant characteristic of LFABP
is thought to result from the methionine groups located
in the cavity of the LFABP binding site [9].
NADPH oxidase (NOX), an enzyme complex respon-
sible for generating superoxide, is activated in rat Kupf-
fer cells in alcoholic liver disease, through induction of
transcription factor NF-b and TNF-a production [10].
However, administration of a methionine choline defi-
cient (MCD) diet to p47 knockout mice, lacking a criti-
cal subunit of the NOX complex, showed that NOX is
not an important contributor of oxidative stress genera-
tion. The p47 knockout mice on an MCD diet devel-
oped NASH with similar pathology as wild type, despite
the lack of a functional NOX enzyme [11].
Currently the only effective therapy to treat NAFLD
and NASH is to decrease body weight in obese and over-
weight individuals, decrease circulating lipids, improve
insulin sensitivity and decrease oxidative damage through
the use of antioxidants [12]. Cocoa and some of its deri-
vatives are a rich source of the flavonoid antioxidants,
catechin and epicatechin [13]. In a high fat diet model of
obesity, rats supplemented with cocoa had normalised
insulin resistance and decreased weight gain. Further-
more, cocoa supplementation decreased gene expression
of fatty acid binding protein in mesenteric adipose tissue
[14]. Consumption of dark chocolate by human subjects
for 15 days has been reported to improve blood pressure
and insulin sensitivity [15]. Cocoa supplementation has
been found to have a beneficial effect in a rat model of
alcoholic steatohepatitis by reducing hepatic fat accumu-
lation, inflammation and necrosis [16].
The current study aimed to investigate if an increase
in oxidative stress was associated with changes in the
expression of LFABP and NOX in a rat model of non
alcoholic steatohepatitis and whether cocoa supplemen-
tation attenuated those changes.
Methods
Animals and diet
All animal experiments and procedures were approved
by the animal welfare committee at Deakin University,
approval number A36/2007. Twelve week old female
Sprague Dawley rats (n = 56, Animal Resources Centre,
Perth, Australia) were housed in pairs with ad libitum
access to food and water. Female rats were selected to
minimise fighting within pairs throughout the study.
Three isocalorically matched diets were used in these
investigations (Table 1). A high fat methionine choline
sufficient (MCS) diet (control); a high fat methionine
choline deficient (MCD) diet; and a high fat methionine
choline deficient diet supplemented with 12.5% cocoa
powder (MCS: A02082003B; MCD: A02082002B;
Research Diets, New Brunswick, USA). The cocoa pow-
der (Natraceutical, Valencia, Spain) contained 12% poly-
phenols, primarily catechin, and trace amounts of
methionine (0.28 mg/g diet) and choline (0.02 mg/g
diet). The MCD diet is a commonly used model of
NASH and is known to cause weight loss [7]. A pilot
study demonstrated that a period of 52 days was a sui-
table time frame to induce NAFLD, based on histologi-
cal grading, and still maintain the body weight of rats
fed the MCD diet. The pilot study indicated that histo-
logically the livers of rats fed the MCD diet were the
same after 42 days of feeding through to 112 days of
feeding. Rats were divided into six groups (Table 2) and
were fed either a MCS or MCD diet for 52 days or one
of four cocoa supplementation regimes: 52 days of
MCD and an additional 28 days of MCD with cocoa
supplementation (C1); 52 days of MCD and an addi-
tional 56 days of MCD with cocoa supplementation
(C2); 80 days of MCD with cocoa supplementation
(C3); 108 days of MCD with cocoa supplementation
(C4). The four feeding regimes were selected to repre-
sent treatment or prevention supplementation modes
that could be applied to NASH patients. Feeding
regimes C1 and C2 were used to test if cocoa supple-
mentation for four or eight weeks could be used to
treat NASH after the disease was established. Whereas,
feeding regimes C3 and C4 were used to see if cocoa
supplementation could be used to prevent or slow the
development of NASH over the same total time periods
used in regimes C1 and C2.
At the conclusion of each regime, animals were fasted
overnight and euthanized at 8 am via a lethal dose of
anaesthetic (70 mg/kg Lethabarb, Therapon, Melbourne,
Australia). Blood samples were collected via cardiac
puncture and the liver, heart, kidneys and pancreas
removed and weighed. One lobe of the liver was fixed in
4% paraformaldehyde (Sigma, Sydney, Australia) and the
remaining portion snap frozen and stored at -80°C for
further analysis.
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Histological analysis
The liver histology was assessed on de-identified slides
by two independent blinded observers after an initial
consensus meeting. Haematoxylin and eosin (H&E)
(Thermo Scientific, Melbourne, Australia) stained sec-
tions were scored for steatosis (0-3) and lobular
inflammation (0-3) according to the revised Kleiner
method [17]. The presence or absence of portal
inflammation was also noted (0-1). Fibrosis was graded
(0-4) using Sirius Red (Sigma, Sydney, Australia)
stained sections [17]. A random subset of 10% of cases
was rescored by each observer. Each animal had dupli-
cate histological specimens prepared, and where scores
differed between duplicates, the slides were rescored
for consensus.
Biochemical parameters and measures of oxidative stress
Plasma triglycerides and glucose levels were determined
using appropriate assay kits according to the manufac-
turer’s instructions (Thermo Scientific, Melbourne, Aus-
tralia). Red blood cell (RBC) and liver tissue glutathione
(GSH), an endogenous antioxidant, was measured via
the GSH recycling method as previously described [18].
Briefly, RBC were obtained by centrifugation of blood
(1000 × g) and 200 μl of RBC was used; 1 g of liver was
homogenized. A change in absorbance (412nm) was
determined after the addition of 5,5’-Dithiobis(2-nitro-
benzoic acid) (Sigma, Sydney, Australia) and corrected
to reduced L-glutathione standard (Sigma, Sydney, Aus-
tralia). Liver GSH was corrected for protein concentra-
tion which was determined via the Bradford method
(BioRad, Sydney, Australia). Dihydroethidium (DHE)
staining (Sigma, Sydney, Australia) was used to detect
levels of superoxide in liver cryosections (14 μm) [19].
DHE fluorescence was quantified using a fluorescence
quantification program, ImageJ (National Institutes of
Health, USA), as a measure of superoxide levels present
in tissue. An ELISA kit was used to measure the DNA
oxidation byproduct 8-hydroxy-2-deoxy guanosine (8-
OH-2dG) (StressMarq Biosciences). DNA was extracted
from 15 mg of liver tissue using a DNA isolation kit
(Promega, Sydney, Australia). Each sample was then
diluted so that 50 μg of DNA was used in the 8-OH-
2dG assay. The competitive immunoassay involves the
binding of free 8-OH-2dG to an antibody coated 96
well plate. The assay and sample concentration of 8-
OH-2dG were carried out as per the manufacturer’s
instructions. Total 8-isoprostane concentrations were
analysed as a marker of oxidative damage to lipids in
liver homogenates prepared for liver GSH using an
enzyme immunoassay (EIA) kit (Cayman Chemicals,
Sydney, Australia) following manufactures instructions.
Prior to analysis liver homogenates were hydrolysed by
addition of 25 μl 2 M NaOH to each 100 μl homoge-
nate. The samples were incubated at 45°C for 2 hours.
Following this, 25 μl 10N HCl acid was added and the
samples were centrifuged for 5 minutes at 12,000 g. The
supernatant was removed and used for the determina-
tion of total 8-isoprostane using the EIA kit. The assay
was based on the competition between 8-isoprostane
and an 8-isoprostane acetycholinesterase (AChE) conju-
gate for a limited number of 8-iso-PGF2a-specific rabbit
anti-serum binding sites, values were expressed as pg/
mg of protein.
Table 1 Diet composition
Catalogue number A02082002B A02082003B A07071301
Ingredients (g) MCD MCS Cocoa (C1 - C4)
Protein 17 17.2 17
Carbohydrate 65.9 65.5 65.9
Fat 9.9 9.9 9.9
L-Alanine 3.5 3.5 2.9
L-Arginine 12.1 12.1 9.9
L-Asparagine-H2O 6 6 4.9
L-Aspartate 3.5 3.5 2.9
L-Cystine 3.5 3.5 2.9
L-Glutamine 40 40 32.8
Glycine 23.3 23.3 19.1
L-Histidine-HCl-H2O 4.5 4.5 3.7
L-Isoleucine 8.2 8.2 6.7
L-Leucine 11.1 11.1 9.1
L-Lysine-HCl 18 18 14.7
L-Phenylalanine 7.5 7.5 6.1
L-Proline 3.5 3.5 2.9
L-Serine 3.5 3.5 2.9
L-Threonine 8.2 8.2 6.7
L-Tryptophan 1.8 1.8 1.5
L-Tyrosine 5 5 4.1
L-Valine 8.2 8.2 6.7
Total L-Amino Acids 171.4 171.4 140.5
Sucrose 455.3 452.3 455.3
Corn starch 150 150 106
Maltodextrin 50 50 50
Cellulose 30 30 0
Corn oil 100 100 86
Mineral mix S10001 35 35 35
Sodium bicarbonate 7.5 7.5 7.5
Vitamin mix V10001 10 10 10
DL-Methionine 0 3 0.2*
Choline bitrate 0 2 0.017*
Cocoa powder 0 0 144
Total 1009.2 1011.2 1034.3
High fat methionine choline sufficient (MCS) diet, high fat methionine choline
deficient (MCD) diet, high fat methionine choline deficient diet with 28 days
of cocoa supplementation (C1), high fat methionine choline deficient diet with
56 days of cocoa supplementation (C2), high fat methionine choline deficient
diet supplemented with cocoa for 80 days (C3) and high fat methionine
choline deficient diet supplemented with cocoa for 108 days (C4).
* Derived from cocoa powder.
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RT-PCR
Total RNA was extracted from 50 mg of frozen liver
using TRI reagent (Astral Scientific, Sydney, Australia)
according to the manufacturer’s specification. The total
RNA concentration was determined by A260/A280 mea-
surement. One microgram of total RNA was reverse
transcribed into cDNA using AMV reverse transcriptase
first strand cDNA synthesis kit according to the manu-
facturer’s protocol (Marligen Biosciences, Sydney, Aus-
tralia). Primers were designed using Primer3. Forward
and reverse primer sequences are shown in Table 3. b-
actin mRNA was quantified and showed no significant
variation between feeding regimes, and all results were
normalised to these values. The amplification of cDNA
samples was carried out using IQ SYBR green™ follow-
ing the manufacturers protocols (BioRad, Sydney, Aus-
tralia) Fluorescent emission data was captured and
mRNA levels were analyzed using the critical threshold
(CT) value [20].Thermal cycling and fluorescence detec-
tion were conducted using the Biorad IQ50 sequence
detection system (BioRad, Sydney, Australia).
Protein extraction and western blot analysis
Liver samples (100 mg) were homogenized and centri-
fuged at 10,000 g at 4°C for 10 minutes. The protein
concentration was determined via the Bradford method
(BioRad, Sydney, Australia); protein samples (10 μg)
were separated via SDS-PAGE on a 4-20% gradient gel
(NuSep, Sydney, Australia) and transferred onto
polyvinylidene difluoride membranes. The membranes
were treated as previously described [21]. Proteins were
visualised using Immune-Star HRP substrate kit
(BioRad, Sydney, Australia). The density of the bands
was quantified using a Chemidoc system (BioRad, Syd-
ney, Australia) and normalised to b-actin expression.
LFABP primary antibody used was a rabbit polyclonal
antibody (1:200). NOX1 primary antibody used was a
rabbit polyclonal antibody (1:200). Secondary antibody
used for both LFABP and NOX1 was a goat anti-rabbit
IgG-HRP conjugated antibody (1:5000). b-actin primary
antibody, mouse anti b-actin (1:200) and secondary goat
anti mouse antibody (1:2000) were used. Antibodies
were purchased from Santa Cruz Biotechnology (CA,
USA).
Statistical analysis
Statistical analysis was performed using SPSS analysis
package (version 17.0), with independent t-tests and
ANOVA with Tukey post-hoc analysis. The categorical
assignments of the various histological aspects of NASH
were statistically analysed by Fishers Exact test. Values
were expressed as mean ± SEM and considered statisti-
cally significant with a p≤0.05.
Results
Histological analysis
The results of the scoring of each of the histological
variables for each of the groups are presented as percen-
tages in Table 4. Histological analysis showed very little
difference in observed steatosis or fibrosis between most
of the groups (Table 4), with a few notable exceptions.
A statistically significant higher steatosis score was seen
in livers from animals fed the MCD diet compared to
animals fed the MCS diet - which showed no or mini-
mal steatosis, scoring 0 (Table 4p < 0.001). This high
steatosis score seen with the pure MCD diet was also
present in each of the cocoa supplemented diet regimes
(again statistically different when compared to the MCS
group, Table 4p < 0.001), with the exception of the C3
diet regime - the livers of which showed a lesser degree
of steatosis when compared to the C1 and C2 diet
Table 3 Primer sequences
Target Sequence
b-actin Forward- TGT CAC CAA CTG GGA CGA TA
Reverse- AAC ACA GCC TGG ATG GCT AC
LFABP Forward- CAT CCA GAA AGG GAA GGA CA
Reverse- CAC GGA CTT TAT GCC TTT GAA
NOX1 Forward- TAC GAA GTG GCT GTA CTG GTT G
Reverse- CTC CCA AAG GAG GTT TTC TGT T
NOX2 Forward- TCA AGT GTC CCC AGG TAT CC
Reverse- CTT CAC TGG CTG TAC CAA AGG
NOX4 Forward- GGA AGT CCA TTT GAG GAG TCA C
Reverse- TGG ATG TTC ACA AAG TCA GGT C
Table 2 Experimental groups, diets and duration of each diet regime
Diet Diet regimes MCS duration (days) MCD duration (days) MCD and cocoa duration (days)
MCS High fat MCS 52 - -
MCD High fat MCD - 52 -
C1 High fat MCD followed by 28 day cocoa supplementation - 52 28
C2 High fat MCD followed by 56 day cocoa supplementation - 52 56
C3 High fat MCD with cocoa supplementation - - 80
C4 High fat MCD with cocoa supplementation - - 108
High fat methionine choline sufficient (MCS) diet, high fat methionine choline deficient (MCD) diet, high fat methionine choline deficient diet with 28 days of
cocoa supplementation (C1), high fat methionine choline deficient diet with 56 days of cocoa supplementation (C2), high fat methionine choline deficient diet
supplemented with cocoa for 80 days (C3) and high fat methionine choline deficient diet supplemented with cocoa for 108 days (C4).
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Table 4 NASH scoring of H&E stained liver sections and fibrosis scores in Sirius Red stained liver sections
Score MCS
(% of cases)
MCD
(% of cases)
C1
(% of cases)
C2
(% of cases)
C3
(% of cases)
C4
(% of cases)
Steatosis 0 100% 0% 0% 0% 0% 0%
1 0% 13% 0% 0% 31% 12%
2 0% 17% 0% 0% 50% 19%
3 0% 70% 100% 100% 19% 69%
Significant MCD, C1, C2, C3, C4 MCS, C3 MCS, C3 MCS, C3 MCS, MCD, C1, C2 MCS
Portal inflammation 0 88% 83% 69% 21% 94% 94%
1 12% 17% 31% 79% 6% 6%
Significant C2 C2 C2 MCS, MCD, C1, C3, C4 C2 C2
Lobular inflammation 0 27% 8% 0% 0% 19% 0%
1 67% 4% 13% 13% 31% 31%
2 2% 57% 64% 64% 50% 56%
3 4% 31% 23% 23% 0% 13%
Significant MCD, C2 MCS N/S MCS N/S N/S
Fibrosis 0 12.5% 0% 0% 0% 0% 0%
1A 0% 18.8% 0% 0% 0% 0%
1B 87.5% 62.5% 12.5% 14.3% 62.5% 37.5%
1C 0% 0% 0% 0% 0% 0%
2 0% 6.3% 62.5% 0% 37.5% 50%
3 0% 12.5% 25% 85.7% 0% 12.5%
4 0% 0% 0% 0% 0% 0%
Significant MCD, C1, C2, C3, C4 MCS, C1, C2, C3, C4 MCS, MCD, C2, C3, C4 MCS, MCD, C1, C3, C4 MCS, MCD, C1, C2, C4 MCS, MCD, C1, C2, C3
Steatosis (0-3), portal inflammation (0-1), lobular inflammation (0-3) and fibrosis (0-4). Groups that are significantly different are listed below values, p < 0.05.
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regimes (Table 4p = 0.007). The presence of portal
inflammation largely paralleled the degree of portal
fibrosis, and each of these was most pronounced in the
C2 group (Table 4 p < 0.001). Lobular inflammation
was seen across the board in the MCD and cocoa sup-
plemented diets to a relatively similar degree, but there
was only weak statistical significance in this observation
for some of the groups when compared to the degree of
lobular inflammation in the MCS group (Table 4 p <
0.05). The lowest fibrosis scores were seen in the MCS
group (Table 4 p < 0.05), and compared to the other
cocoa supplementation groups, the livers from the ani-
mals on the C3 diet had the lowest fibrosis scores
(Table 4 p < 0.05). Cirrhosis (Fibrosis score 4) was not
seen in any of the livers from any of the animals in this
study (Figure 1; Table 4).
Organ weight and body weight
Animals on the MCD and C1-C4 diet regimes had lower
body weight compared to MCS animals (Table 5p <
0.001). Heart, kidney and pancreas weight were the
same for all groups (data not shown). In contrast, liver
weight represented a greater portion of body weight in
the MCD and C1-C4 diet regimes compared to rats fed
the MCS diet (Table 5p < 0.001). In addition, liver
weight was significantly lower in the C2 diet regime (3.7
± 0.1%) when compared to the MCD, C3 and C4 diet
regimes, 4.4 ± 0.1%, 5.2 ± 0.2% and 4.1 ± 0.1%, respec-
tively (Table 5p < 0.01). Average food intake over the
duration of each dietary regime was in line with body
weight; food intake did not differ between the cocoa
regimes (Table 5).
Biochemical parameters
Circulating triglyceride levels were lower following con-
sumption of the MCD diet when compared to the MCS
diet (Table 5p < 0.001). This lower level was enhanced
by the administration of cocoa supplement, resulting in
a lower level of circulating triglycerides when compared
to the MCD diet (Table 5p < 0.01). Duration of cocoa
supplement enhanced this effect with C2 resulting in
lower triglyceride levels when compared to C1 (Table
5p = 0.02).
Circulating glucose levels were also lower in animals
on the MCD diet irrespective of cocoa supplementation
when compared to MCS (Table 5p < 0.05). C1 and C2
resulted in significantly lower glucose when compared
to C3 (Table 5p < 0.01).
Measures of oxidative stress
Superoxide (DHE) levels were significantly higher in
MCD fed animals compared to MCS fed animals (Table
5p < 0.001). Furthermore, superoxide levels were two
fold higher in the C1, C2 and C4 groups when com-
pared to animals fed the MCS diet (Table 5p < 0.001).
C3 had the lowest superoxide levels when compared to
the other cocoa groups (Table 5p < 0.01).
Liver GSH was twofold higher in MCD animals when
compared to MCS diet fed animals (Table 5p < 0.01).
Liver GSH was observed to be lower in all cocoa groups
when compared to MCD (Table 5p < 0.001). In addi-
tion, C4 had significantly higher liver GSH when com-
pared to the C1 and C3 diet regimes (Table 5p < 0.05).
Animals on the MCS diet had significantly lower RBC
GSH when compared to those on the MCD and cocoa
regimes (Table 5p < 0.01), with the exception of animals
on the C4 diet regime. Animals on the C1 and C2 diet
regimes had significantly higher RBC GSH levels, two
fold and three fold respectively, when compared to
MCS, MCD, C3 and C4 diet regimes (Table 5p < 0.01).
Liver 8-OH-2dG levels were significantly lower in
MCD fed animals compared to MCS fed animals (Table
5p < 0.04). In contrast there was a significantly higher
level of 8-OH-2dG in groups C1 and C2 compared to
MCS and MCD fed animals (Table 5p < 0.001).
Whereas, 8-OH-2dG levels in groups C3 and C4 were
significantly lower than the levels observed in C1 and
C2 (Table 5p < 0.001).
Liver 8-isoprostane levels were significantly higher in
MCD fed animals and group C2 compared to MCS fed
animals (Table 5p < 0.02). In contrast C3 has signifi-
cantly lower levels of 8-isoprostane compared to MCD
and C2 groups (Table 5p < 0.03).
LFABP mRNA and Protein Expression
Lower levels of LFABP mRNA were observed following
MCD diet consumption when compared to the MCS
diet (Figure 2A, p < 0.001), but LFABP mRNA was 56
fold higher in animals fed the C1 diet when compared
to the MCD diet (Figure 2A, p < 0.01). There was 20
fold lower LFABP protein levels in animals fed the
MCD when compared to the MCS diet (Figure 2B, p <
0.001). The animals fed the MCS diet had higher levels
of LFABP protein when compared to C2, C3 and C4
diet regimes (Figure 2B, p < 0.001). The C1 diet regime
also showed higher levels of LFABP protein when com-
pared to MCD (Figure 2B, p < 0.01).
NOX mRNA and Protein Expression
A fivefold depression of the NOX1 mRNA was
observed following MCD diet consumption, with or
without cocoa supplementation, when compared to the
MCS diet (Figure 3A, p < 0.05). No difference was
found in the mRNA levels of NOX2 and NOX4
between diet regimes. NOX1 protein levels were 20
fold higher in the C2 group when compared to MCS,
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MCD, C1, C3 and C4 diet regimes (Figure 3B, p <
0.01). Both C3 and C4 diet regimes had significantly
higher NOX1 protein levels compared to the MCD
diet (Figure 3B, p < 0.03).
Discussion
The present study was carried out to determine if oxida-
tive stress was associated with changes in the expression
of LFABP and NOX in a rat model of non alcoholic
A
KE
PJD
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B H N
MG
F L R
Q
I
Figure 1 Histological examination of liver sections by H&E stain (at left), Sirius Red stain (at middle) and DHE stain (at right). H&E stain
(A-F): MCS diet (A), MCD diet (B), C1 (C), C2 (D), C3 (E), C4 (F). Sirius Red stain of fibrosis (G-L): MCS diet (G), MCD diet (H), C1 (I), C2 (J), C3 (K), C4
(L). DHE stain of superoxide (M-R): MCS diet (M), MCD diet (N), C1 (O), C2 (P), C3 (Q), C4 (R). Bar = 100 μm.
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steatohepatitis and whether cocoa supplementation atte-
nuated those changes. The results indicate an associa-
tion between the MCD diet and levels of LFABP in the
development of NASH in a well established model of
the disease. Levels of LFABP mRNA and protein were
significantly lower in animals on the MCD diet in com-
parison to animals on the MCS diet. Suppression of
LFABP may be another mechanism by which this diet
causes an increased fat content in the liver in addition
to impairing phosphatidylcholine synthesis [7]. Low
levels of LFABP may lead to an inability of the hepato-
cyte to shuttle long chain fatty acids to different intra-
cellular destinations for metabolism [22], resulting in
higher levels of hepatic fat content in MCD animals as
evident from the histological analysis (Figure 1; Table
4). Supplementation of MCD diet with cocoa in the C1
diet regime significantly increased levels of LFABP
mRNA (Figure 2A), which we postulate leads to a
restoration in trafficking of fatty acids within the hepa-
tocyte; however this did not lead to a lower degree of
observed steatosis (Table 4). Increased levels of LFABP
may reduce oxidative damage by binding long chain
fatty acids to its methionine residues [23]. Low levels of
LFABP in MCD fed animals may therefore result in
increased oxidative damage due to its ability to act as an
endogenous antioxidant [9]. The increase in LFABP
mRNA in the C1 diet regime (Figure 2A) showed a
similar pattern at the protein level (Figure 2B). A
decrease in LFABP may be linked to the liver’s inability
to cope with lipotoxicity, which is thought to contribute
to NASH [24]. LFABP has been found to be upregulated
in the presence of long chain fatty acids and has been
directly implicated in hepatic regeneration [25]. This
may be correlated to the effects of LFABP stimulation of
PPAR-a to further increase LFABP mRNA. Findings in
rat models indicate an increase in LFABP during hepatic
regeneration, supporting the role of this protein in
maintaining the integrity of the hepatocyte [25]. LFABP
deregulation, as shown by an inverse relationship
between the ratio of LFABP and fat content in the liver,
has been correlated with obesity and type 2 diabetes in
the Israeli sand rat [26]. This is further supported by a
silencing of LFABP in patients with hepatocellular ade-
noma who had a mutation in the hepatocyte nuclear
factor 1a, causing impaired trafficking of fatty acids,
leading to steatosis [27]. Since LFABP is an abundant
protein in hepatocytes, it may provide a major source
of intracellular antioxidant activity. Purified LFABP has
been tested for its antioxidant capacity [9] and is able
to quench up to 66% of free radicals generated from
superoxide. This is in agreement with our findings of
lower LFABP being present at both the mRNA level
(Figure 2A) and protein level (Figure 2B) in animals
with MCD derived fatty liver disease in comparison to
the animals fed the MCS diet. In addition, higher levels
of superoxide fluorescence and 8-isoprostane were evi-
dent in the MCD fed animals as compared to the MCS
fed animals (Table 3 and 5; Figure 1M and 1N),
further supporting an inverse association between
levels of LFABP and levels of oxidative stress. How-
ever, supplementation with cocoa in the C1 and C2
diet regimes resulted in higher superoxide and 8-OH-
2dG levels when compared to MCS animals. This may
be related to higher degree of observed steatosis in
Table 5 Biochemical parameters and measures of oxidative stress
MCS MCD C1 C2 C3 C4
Food intake (g/pair/day) 24.4 ± 1.6 16.4 ± 0.5
MCS
13.4 ± 0.4
MCS
13.8 ± 0.6
MCS
12.4 ± 1.5
MCS
9.6 ± 0.5
MCS, MCD
Body weight
(g)
283 ± 10 185 ± 4
MCS
192 ± 3
MCS
195 ± 7
MCS
188 ± 5
MCS
184 ± 5
MCS
Liver/body weight (%) 2.7 ± 0.1 4.4 ± 0.1
MCS
4.5 ± 0.3
MCS
3.7 ± 0.1
MCS, MCD
5.2 ± 0.2
MCS, C2
4.1 ± 0.1
MCS, C2
DHE
(arbitrary units)
42.3 ± 2.1 71.6 ± 3.6
MCS
88.1 ± 1.0
MCS
87.9 ± 1.0
MCS
74.8 ± 3.7
MCS, C1, C2
88.8 ± 2.5
MCS, C3
Liver 8-OH-2dG
(pg/ml)
192 ± 12 145 ± 5
MCS
265 ± 14
MCS, MCD
304 ± 12
MCS, MCD
205 ± 8
MCD, C1, C2
172 ± 7
C1, C2
Liver 8-isoprostane
(pg/mg protein)
110 ± 12 155 ± 7
MCS
137 ± 9 163 ± 12
MCS
121 ± 5
MCD, C2
157 ± 7
Liver GSH
(mg)
495 ± 64 1090 ± 156
MCS
120 ± 8
MCD
127 ± 9
MCD
106 ± 10
MCD
142 ± 6
MCD, C1, C3
RBC GSH
(mg)
144 ± 8 177 ± 7
MCS
359 ± 26
MCS, MCD
432 ± 70
MCS, MCD
193 ± 15
MCS, C1, C2
120 ± 7
C1, C2
Glucose
(mmol/L)
9.1 ± 0.4 6.8 ± 0.1
MCS
6.5 ± 0.2
MCS
6.0 ± 0.2
MCS
7.7 ± 0.1
MCS, C1, C2
6.6 ± 0.4
MCS
Triglycerides (mmol/L) 1.25 ± 0.05 0.99 ± 0.04
MCS
0.70 ± 0.02
MCD
0.66 ± 0.01
MCD, C1
0.71 ± 0.03
MCD
0.72 ± 0.01
MCD
Values are presented as mean ± SEM. Groups that are significantly different are listed below values, p < 0.05.
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these groups (Table 4). Slightly lower superoxide and
8-OH-2dG levels were seen when animals were on the
C3 diet regime. This C3 cocoa group had lower levels
of steatosis when compared to MCD, C1 and C2 diet
regimes. Further to this, lower levels of lobular
inflammation and fibrosis were observed in these
groups. It cannot be concluded that the higher levels
of superoxide seen in the cocoa supplemented diets
are as a result of the cocoa instead of the MCD, as the
animals supplemented with cocoa were on the MCD
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Figure 2 Quantification of LFABP at the mRNA and protein levels. (A) LFABP mRNA levels. (B) LFABP protein concentration. *Significant
difference compared to MCS, p < 0.001. **Significant difference compared to MCD, p < 0.01. ***Significant difference compared to MCD, C2, C3
and C4, p < 0.001.
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diet longer than the MCD control group, dependent
on the time of cocoa supplementation.
The quantification of mRNA detected differences in
the levels of NOX1 mRNA expression, but no change
observed in NOX2 and NOX4 mRNA expression
between the different diet regimes. NOX1 mRNA expres-
sion levels were lower in all groups fed the MCD diet in
comparison to those on the MCS diet (Figure 3A). The
effect of the dietary regimes on NOX1 protein levels was
different to that of mRNA expression levels (Figure 3B),
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Figure 3 Quantification of NOX1 at the mRNA and protein levels. (A) NOX1 mRNA levels. (B) NOX1 protein concentration. *Significant
difference compared to MCS, p≤0.05. **Significant difference compared to MCD, p≤0.03. #Significant difference compared to MCS, MCD, C1, C3
and C4, p≤0.01.
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indicating that NOX1 may be regulated at the protein
level, rather than the gene level. Higher concentrations of
NOX1 protein were observed in animals on the C2 diet
regime. Gene knockout of gp91phox, a vital regulatory
component of the assembly of NOX, showed no differ-
ence in the pathology of MCD induced NASH in mice
compared to wildtype [11]. This would indicate that
NOX generation of ROS is not a key factor in the devel-
opment of MCD induced NASH, which is supportive of
our findings in NOX mRNA expression. However, a link
can be seen between NOX1 protein levels and presence
of portal inflammation in animals on the C2 diet regime,
with higher NOX1 levels measured and a greater propor-
tion of portal inflammation observed in comparison to
rats on the other diets. In alcoholic liver disease, mice fed
ethanol via the Tsukamoto-French intragastric enteral
method, NOX was found to increase ROS and activate
NF-B, which led to an increase in TNF-a in livers. This
leads not only to an increase in oxidative damage but
also an increase in synthesis of fatty acids causing hepatic
damage [28].
Histological analysis of livers from rats fed the MCD
diet showed greater steatosis in comparison to those on
the MCS diet (Figure 1). Steatosis has been reported by
others at week 2 of MCD feeding in rat livers [7]. The
severity of steatosis was not observed to be less in any
of the groups in which cocoa was added to the MCD
diet, however there was a statistically significant lower
degree of steatosis observed in livers of animals fed the
C3 diet regime. It is extrapolated from this observation
that the antioxidant properties of cocoa are more likely
to affect levels of reactive oxidative species rather than
hepatocyte fat content. This is supported by a lower
level of ROS as determined by DHE staining and 8-OH-
2dG in the C3 diet regime when compared to C1 and
C2 diet regimes (Table 5). Antioxidants derived from
cocoa may play a role in suppressing the activation of
hepatic stellate cells to form fibrotic tissue, as fibrosis
was not as severe in the animals on the C3 diet regime,
a group which had lower scores for steatosis and lobular
inflammation compared to other MCD and MCD/cocoa
regimes (Table 4).
Circulating triglyceride levels were lower in the the
MCD group compared to the control. However cocoa
supplementation was associated with even lower circu-
lating triglyceride levels (Table 5). Re-esterification of
fatty acids into triglycerides has been described as a
mechanism protecting the liver from lipotoxicity as
inflammation, oxidative damage and fibrosis decrease
[29]. Lower levels of circulating triglycerides (Table 5)
found in our study are in line with increased severity of
NAFLD as shown by increased steatosis scores in Table
4. The reduction in body weight on MCD possibly led
to an increase in glucose being used as an energy source
causing a reduction in the circulating levels of glucose
(Table 5). The MCD diet has been previously reported
to decrease glucose and improve insulin sensitivity
whilst not having a dampening effect on the develop-
ment of hepatic inflammation or fibrosis [29]. Although
the MCD diet caused weight loss, liver weight increased
as a result of higher fat content as seen in the histology
of these samples (Figure 1; Table 4).
RBC GSH levels were significantly higher in the C1
and C2 groups (Table 5). This suggested that cocoa
could be used to increase the availability of the reduced
form of GSH to act as an antioxidant within RBC’s and
possibly the circulation. Liver GSH on the other hand
was much lower in all cocoa supplemented animals
when compared to those on the MCS and MCD diets.
Low levels of this endogenous antioxidant in the cocoa
supplemented animals may be due to the higher bioa-
vailability of exogenous antioxidants derived from the
cocoa. The accumulation of exogenous antioxidants
from cocoa may therefore be beneficial in providing suf-
ficient antioxidants to quench ROS in NASH. Our find-
ings on hepatic GSH are not in agreement with most
other studies which show a depletion of this endogenous
antioxidant [7].
Despite the novel data presented from the current
study there are limitations associated with the findings.
Due to restrictions imposed by the institutional animal
welfare committee it was not possible to include addi-
tional MCD fed rats for 80 and 108 days to match
cocoa supplementation groups C1 - C4. Although pilot
data indicated histologically the livers of rats fed the
MCD diet are similar from 42 - 112 days, it cannot be
excluded that the effects associated with cocoa supple-
mentation in the liver are not to prolonged MCD feed-
ing. It is possible, but unlikely, that the results observed
following cocoa supplementation are not due to the
antioxidants present in the cocoa, but rather the trace
amounts of methionine and choline present in the
cocoa. However if the trace amounts of methionine and
choline present in the cocoa were responsible for the
results observed it would be expected that data collected
from the cocoa supplemented groups would more clo-
sely resemble the MCS group and not the MCD group.
Finally although the MCD diet is a commonly used
model of NASH there are a number of limitations asso-
ciated with comparing the model to metabolic changes
in human NAFLD/NASH [7]. These limitations include
weight loss in rats fed the MCD diet, whereas NASH
patients are typically overweight or obese [1,7]. The
accumulation of fat within the liver of rats fed the MCD
diet is due to a disruption of the export of hepatic lipids
and subsequent lipotoxicity, unlike the human situation
where the excessive hepatic fat import or storage is
thought to occur [1,7].
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Conclusions
Our investigations indicate that the intracellular lipid
transporter LFABP may play a key role in the estab-
lishment of MCD induced NAFLD and NASH not
only by shuttling long chain fatty acids within the cell,
but possibly by also acting as an antioxidant. Further-
more, the decreased levels of LFABP in the MCD
model of NASH may suggest impairment in the func-
tioning of LFABP in this disease. A cocoa rich diet is
able to act as a rich source of exogenous antioxidants
with no depletion of RBC GSH. However, this does
not lead to lower hepatic superoxide and 8-OH-2dG
levels. During the supplementation with the C1 diet
regime, cocoa was associated with higher levels of
LFABP compared to the MCD diet. There is depletion
in the levels of NOX1 mRNA in animals on the MCD
diet. NOX1 however is higher at the protein level in
the animals on the C2 regime. The C2 regime simulta-
neously increased steatosis, portal inflammation and
fibrosis, suggesting a possible role for NOX in inflam-
mation and fibrosis in the rat NASH liver. As NASH
develops in humans suffering from obesity and insulin
resistance, further investigations into LFABP in the
development of NASH in these patients is warranted.
As fibrosis was less prominent in animals on the C3
diet regime, the role of antioxidants in influencing stel-
late cell activation and the development of fibrosis
should be investigated.
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